AACN Influence Research Grants support medical inquiry that drives modification in high acuity and crucial treatment nursing practice. Priority tasks address gaps in clinical research at the business or system level and translation of these results to bedside clinicians. Projects include usage of technology to assess individuals and manage outcomes; methods to create a curing and humane environment; and procedures and systems to optimize high acuity and important care nursing. This year, AACN awarded two Influence Research Grants, that may boost to three in 2013.COBALZ is currently actively seeking other development and licensing companions for the rest of the global market.
AVEO second-one fourth total revenues increase to $15.6 million AVEO Pharmaceuticals, Inc. , a biopharmaceutical business focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development and business accomplishments, and announced financial results for the one fourth ended June 30, 2010. AVEO was very productive in the next one fourth, said Tuan Ha-Ngoc, president and ceo of AVEO. Specifically, we received orphan drug designation for tivozanib from the European Medications Agency, we presented promising clinical data from studies of tivozanib and AV-299, presented new insights relating to Notch, among our discovery-stage targets, and co-authored a paper highlighted in Nature Reviews Cancer on our novel murine models which are a core part of our proprietary malignancy biology platform.